Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Bezetabart Debotansine · STRO-001, SP7675

Antibody-drug conjugate · Cytotoxic, directed at CD74 · developed by Sutro Biopharma

Phase 1 Most advanced trial (none active)
STRO Developer
1 Registered trials

What is Bezetabart Debotansine?

Bezetabart Debotansine is an antibody-drug conjugate in which an anti-CD74 antibody is site-specifically linked to a non-cleavable maytansinoid microtubule-disrupting warhead. After binding CD74 on tumor cells and internalization, the maytansinoid inhibits cell division and growth. It is studied in B-cell lymphomas and multiple myeloma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
STRO-001, SP7675
Drug type
Antibody-drug conjugate
Targets
CD74, tubulin (secondary target)
Mechanism
Cytotoxic, directed at CD74
Pathways
microtubule assembly/disassembly, cell division, MIF-CD74 signaling
Therapy area
Oncology
Developer
Sutro Biopharma, Inc. (STRO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
0D8BWL78LD

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03424603 Phase 1 B-cell Lymphoma Completed STRO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

B Cells--TumorsB-cell LymphomaDiffuse Large B Cell LymphomaFollicular LymphomaIndolent LymphomaMantle Cell LymphomaMultiple MyelomaNon Hodgkin Lymphoma

More from Sutro Biopharma

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the STRO page.

Follow STRO, the company behind Bezetabart Debotansine

See STRO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

STRO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.